Publications by authors named "D T Boumpas"

Objective: Glucocorticoid (GC) tapering and withdrawal to reduce damage represents a key aspect of the European Alliance of Associations for Rheumatology (EULAR) SLE recommendations. However, optimal strategies for relapse-free GC cessation remain ill-defined. We characterised clinical predictors and their combined effect on flares in patients with SLE who discontinued GC.

View Article and Find Full Text PDF

Objectives: To evaluate the combination of novel colour Doppler ultrasound (CDUS), greyscale ultrasound (GSUS), and oscillometric indices of macroangiopathy in patients with idiopathic inflammatory myopathies (IIM). Second, to explore the associations between these imaging markers and both patient-related and disease-related characteristics, as well as traditional cardiovascular (CV) risk factors.

Methods: We conducted CDUS to evaluate arterial compliance markers, specifically the resistance (RI) and pulsatility (PI) indices, both in the common (CCA) and internal carotid arteries (ICA) of patients with IIM and healthy controls.

View Article and Find Full Text PDF

During the coronavirus disease-19 (COVID-19) pandemic, there was an unprecedented requirement for hospital bed availability. The present study aimed to examine the characteristics and outcomes of patients hospitalized in a COVID-19 unit that operated as a novel middle-step unit in Greece. The present study aimed to determine whether the middle-step unit supported the central general hospitals; thus, highlighting the potential of these models in future pandemics.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates how belimumab, a drug for systemic lupus erythematosus (SLE), affects blood gene expression and whether early treatment response can be predicted through blood tests.
  • RNA sequencing was conducted on blood samples from 45 active SLE patients before and after 6 months of treatment, revealing significant changes in gene expression related to immune cell activity and disease severity.
  • Results indicate that belimumab reduces specific immune pathways and may reverse disease markers, with a model predicting treatment response based on 50 genes showcasing 84% accuracy.
View Article and Find Full Text PDF